Patents Assigned to Max Planck Institute
  • Patent number: 10851130
    Abstract: The present disclosure discloses the chemical synthesis method of the Plesiomonas shigelloides serotype O51 O-antigen oligosaccharide, belonging to the field of chemistry. Source-abundant D-glucose, L-fucose, D-glucosamine and the like are used as raw materials to prepare three glycosylation building blocks, the synthetic route composed of 11 reaction modules is designed, and through the optimization of protecting group and the optimization of the time of introducing functional group, the preparation of the target oligosaccharide chain is successfully achieved. The oligosaccharide chain prepared in the present disclosure has the advantages of cheap and easy-to-get raw materials, and simple and easy-to-repeat preparation method. The present disclosure will have good application prospects in the aspects of development of new drugs and vaccines of Plesiomonas shigelloides, and the like.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 1, 2020
    Assignees: Jiangnan University, Max Planck Institute of Colloids and Interfaces
    Inventors: Jian Yin, Jing Hu, Peter Seeberger, Chunjun Qin
  • Patent number: 10512605
    Abstract: The present disclosure discloses an integrated nano system for liver-targeting co-delivery of genes/drugs and a preparation method, belonging to the field of biomedicines. In the disclosure, a plurality of functions are integrated in a carrier having good biocompatibility and safety, a nucleic acid/drug-loading copolymer portion having a pH-stimulating response function is formed by poly(N,N-dimethylaminoethyl methacrylate) (PDMAEMA) grafted with poly(3-azido-2-hydroxypropylmethacrylate) (PGMA-N3), and a fluorescence-based imaging component Rhodamine B (RhB) and galactose are used as targeting ligands. The drug delivery system provided by the present disclosure is safe, is capable of taking a synergistic effect of gene/drug therapy, and is expected to play a great role in clinical application.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: December 24, 2019
    Assignees: Jiangnan University, Max Planck Institute of Colloids and Interfaces
    Inventors: Jian Yin, Jing Hu, Peter Seeberger, Zhou Ye
  • Publication number: 20180064712
    Abstract: The present invention encompasses methods of reducing inflammatory immune cell activation and inflammation via inhibiting mitochondrial fission.
    Type: Application
    Filed: June 8, 2017
    Publication date: March 8, 2018
    Applicant: Max Planck Institute
    Inventors: Erika L. Pearce, Michael D. Buck, David O'Sullivan, Francesc Baixauli
  • Publication number: 20130338744
    Abstract: Graphene, can be used to make an implantable neuronal prosthetic which can be indefinitely implanted in vivo. Graphene electrodes are placed on a 3C—SiC shank and electrical insulation is provided by conformal insulating SiC. These materials are not only chemically resilient, physically durable, and have excellent electrical properties, but have demonstrated a very high degree of biocompatibility. Graphene also has a large specific capacitance in electrolytic solutions as well as a large surface area which reduces the chances for irreversible Faradaic reactions. Graphene can easily be constructed on SiC by the evaporation of Si from the surface of that material allowing for mechanically robust epitaxial graphene layers that can be fashioned into electrodes using standard lithography and etching methods.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 19, 2013
    Applicants: Max-Planck-Institute for Solid State Research, University of South Florida
    Inventors: Christopher Leroy Frewin, Stephen E. Saddow, Camilla Coletti
  • Patent number: 6842704
    Abstract: A tumor necrosis factor-? converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: January 11, 2005
    Assignees: Immunex Corporation, Max-Planck-Institute for Biochemistry, Wyeth
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Publication number: 20040265983
    Abstract: A tumor necrosis factor-&agr; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Application
    Filed: February 24, 2004
    Publication date: December 30, 2004
    Applicants: IMMUNEX CORPORATION; MAX-PLANCK-INSTITUTE FOR BIOCHEMISTRY, WYETH
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Patent number: 6531235
    Abstract: A structure containing a ferroelectric material comprises a substrate comprising silicon, a buffer layer formed on the substrate, and a non-c-axis-oriented, electrically-conductive template layer formed on the buffer layer. The template layer comprises a perovskite oxide compound. A non-c-axis-oriented, anisotropic perovskite ferroelectric layer is formed on the template layer.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: March 11, 2003
    Assignee: Max-Planck-Institute für Mikrostrukturphysik
    Inventors: Ho Nyung Lee, Stephan Senz, Alina Visinoiu, Alain Pignolet, Dietrich Hesse, Ulrich Gösele